

## Erratum to: A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia

Yoshiaki Ogawa · Michinori Ogura · Tatsuya Suzuki · Kiyoshi Ando · Toshiki Uchida · Yukari Shirasugi · Kensei Tobinai · Je Hwan Lee · Masazumi Kase · Koichi Katsura · Tomomitsu Hotta

Published online: 19 December 2013  
© The Japanese Society of Hematology 2013

### Erratum to: Int J Hematol (2013) 98:164–170 DOI 10.1007/s12185-013-1393-x

A published-ahead-of-print version of this article was made available online on 12 July 2013. It was subsequently determined that the reported drug concentration measurements were from a manner which deviated from the Standard Operation Procedures (SOP) in place at the time of sample analysis. This deviation involved an enzyme-linked immunosorbent assay (ELISA) which was used for measurement of plasma ofatumumab concentrations in Study OMB112758, involving 45 samples on one specific

The online version of the original article can be found under doi:10.1007/s12185-013-1393-x.

Y. Ogawa (✉) · K. Ando · Y. Shirasugi  
Department of Hematology and Oncology, Tokai University  
School of Medicine, Shimokasuya 143, Isehara,  
Kanagawa 259-1193, Japan  
e-mail: yoshioga@is.icc.u-tokai.ac.jp

M. Ogura · T. Suzuki · T. Uchida  
Department of Hematology and Oncology, Nagoya Daini Red  
Cross Hospital, Nagoya, Japan

K. Tobinai  
Department of Hematology, National Cancer Center Hospital,  
Tokyo, Japan

J. H. Lee  
Department of Hematology, Asan Medical Center, Seoul, Korea

M. Kase · K. Katsura  
GlaxoSmithKline K.K., Tokyo, Japan

T. Hotta  
National Hospital Organization Nagoya Medical Center,  
Nagoya, Japan

immunoassay plate among a total of 307 samples in this study. Re-measurement of these impacted samples was performed in compliance with the current SOP, and the pharmacokinetic parameters were re-calculated. The correct data and figure appear below. This substitution of data does not impact on any scientific findings and outcomes, logic of discussion and the conclusion of the manuscript. The authors wish to apologize to readers and editorial office for any inconvenience this might cause.

On the 5th page on line 4 in the right column, “834  $\mu\text{g/mL}$ ” should be “832  $\mu\text{g/mL}$ ”.

On the 5th page on line 10 in the right column, “71, 1691 and 865  $\mu\text{g/mL}$ ” should be “69, 1670 and 865  $\mu\text{g/mL}$ ”.

On the 5th page on line 11 in the right column, “1524 h  $\mu\text{g/mL}$ ” should be “1506 h  $\mu\text{g/mL}$ ”.

On the 5th page on line 12 in the right column, “200904 h  $\mu\text{g/mL}$ ” should be “200182 h  $\mu\text{g/mL}$ ”.

On the 6th page on line 27 in the right column, “1691  $\mu\text{g/mL}$ ” should be “1670  $\mu\text{g/mL}$ ”.

There are errors in Fig. 2. The correct version is given below.




Fig. 2 Mean (+SD) plasma concentration of ofatumumab–time plots

There are errors in Table 6. The correct version is given below.

**Table 6** Pharmacokinetic parameters of ofatumumab

	Day 1 300 mg ( <i>N</i> = 8)	Week 7 <sup>a</sup> 2000 mg ( <i>N</i> = 8)	Week 24 <sup>b</sup> 2000 mg ( <i>N</i> = 7)
$C_{\max}$ ( $\mu\text{g/mL}$ )	69 (43–111)	1670 (1325–2106)	865 (659–1136)
$C_{\min}$ ( $\mu\text{g/mL}$ )	–	832 (540–1283)	122 (29–518) <sup>c</sup>
AUC <sup>d</sup> (h $\mu\text{g/mL}$ )	1506 (594–3820)	200182 (139285–287703)	216678 (114238–410979)
$t_{1/2}$ (h)	9.6 (5.0–18.2)	331 (224–491)	300 (182–495)
CL (mL/h)	199 (79–505)	10.0 (7.0–14.4)	9.2 (4.9–17.5)
$V_{\text{ss}}$ (mL)	3668 (2325–5788)	1334 (929–1915)	3069 (2123–4437)
MRT (h)	18.4 (10.4–32.5)	478 (333–686)	464 (264–817)

Geometric mean (95 % confidence interval)

<sup>a</sup> After final (8th) weekly dose

<sup>b</sup> After final (4th) monthly dose

<sup>c</sup> *N* = 8

<sup>d</sup> AUC<sub>0–inf</sub> for day 1, AUC<sub>0–168</sub> for week 7, AUC<sub>0–672</sub> for week 24